GlassScriptPhysician profile
Jeffrey Sheridan
NPI 1245261619
$3,864.60
in general payments reported to CMS, 2019-2025
22 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $123 · 2021: $475 · 2022: $632 · 2023: $480 · 2024: $653 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,216 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,216.43 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,056.89 | 2019-2025 | Argos, Hydrus Microstent, Centurion |
| Abbvie INC. | $1,035.93 | 2022-2025 | Durysta, Xen Glaucoma Treatment System |
| Aerie Pharmaceuticals, INC. | $284.75 | 2019-2021 | |
| Glaukos Corporation | $260.49 | 2025 | Idosetr |
| Allergan, INC. | $199.75 | 2020-2022 | |
| Ocular Therapeutix, INC. | $191.34 | 2025 | Dextenza |
| Harrow Eye, LLC | $148.18 | 2024-2025 | Vevye |
| Kala Pharmaceuticals, INC. | $112.28 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $94.81 | 2020-2022 | |
| Sight Sciences, INC. | $89.86 | 2019-2020 | |
| Biotissue Holdings INC. | $80.06 | 2024-2025 | |
| Notal Vision, INC. | $68.84 | 2024 | Foresee Home |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| New World Medical,INC. | $25.21 | 2024-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Tarsus Pharmaceuticals, INC. | $23.95 | 2024 | Xdemvy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $22.93 | 2024 | Rayone Emv, Rayone Aspheric, Rayner Cataract Set 1 |
| Oyster Point Pharma, INC. | $22.04 | 2022 | |
| Sun Pharmaceutical Industries INC. | $18.22 | 2022 | |
| Bausch & Lomb Americas INC. | $17.84 | 2023 | Miebo |
| Shire North American Group INC | $16.71 | 2019 | |
| Horizon Therapeutics Plc | $15.23 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Sheridan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.